<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01607385</url>
  </required_header>
  <id_info>
    <org_study_id>116511</org_study_id>
    <nct_id>NCT01607385</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.</brief_title>
  <official_title>A Single Blind, Randomized, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Tolerability,Pharmacokinetic and Pharmacodynamic Parameters of Repeat Doses of GSK2330672 in Healthy Volunteers, Given Alone and With a Single Day of Dosing With GSK1614235</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      A single blind, randomized, placebo-controlled, dose escalating study to evaluate the safety,&#xD;
      tolerability, pharmacokinetic and pharmacodynamic parameters of repeat doses of GSK2330672 in&#xD;
      healthy volunteers, given alone and with a single day of dosing with GSK1614235&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 18, 2012</start_date>
  <completion_date type="Actual">December 3, 2012</completion_date>
  <primary_completion_date type="Actual">December 3, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory tests for safety.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Regular clinical chemistry and hematology panels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bristol Stool Form Scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>Frequency of bowel movements and quality of stool samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>Tolerability of possible gastic side effets.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measures of GSK2330672.</measure>
    <time_frame>Change from baseline at 2 weeks.</time_frame>
    <description>AUC, Cmax, tmax, t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmcokinetic measures of GSK2330672, GSK1614235, GSK2313533, and GSK2313537.</measure>
    <time_frame>Full profiles on Day 13.</time_frame>
    <description>AUC, Cmax, tmax and t1/2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>GSK2330672</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2330672</intervention_name>
    <description>BID, repeat doses</description>
    <arm_group_label>GSK2330672</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>BID, repeat doses</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1614235</intervention_name>
    <description>BID, co-dosed BID with last dosing day of active/placebo repeat doses</description>
    <arm_group_label>GSK2330672</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring. A subject with a clinical abnormality or laboratory parameters&#xD;
             outside the reference range for the population being studied may be included only if&#xD;
             the Investigator and the GSK Medical Monitor agree that the finding is unlikely to&#xD;
             introduce additional risk factors and will not interfere with the study procedures.&#xD;
             Laboratory assessments may be repeated if outside of normal ranges. The Investigator&#xD;
             may interpret screening vital sign data based on the subject's age, physical state and&#xD;
             level of fitness. Subjects with vital sign readings marginally outside the normal&#xD;
             ranges below may be included in the study if in the Investigator's opinion these&#xD;
             values are not clinically significant and will not present a safety risk or affect&#xD;
             study assessments.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form. Subjects must understand the&#xD;
             aims, investigational procedures and possible consequences of the study and must be&#xD;
             able to understand and comply with protocol requirements, instructions and&#xD;
             protocol-stated restrictions.&#xD;
&#xD;
          -  Male or female between 18 and 60 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of: Non-childbearing potential&#xD;
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or&#xD;
             postmenopausal defined as 12 months of spontaneous amenorrhea. In questionable cases,&#xD;
             a blood sample with simultaneous follicle stimulating hormone greater than 40 MlU/ml&#xD;
             and estradiol less than 40 pg/ml (less than 140 pmol/L) is confirmatory in the absence&#xD;
             of a clear postmenopausal history; Females on hormone replacement therapy must&#xD;
             discontinue hormone replacement therapy to allow confirmation of post-menopausal&#xD;
             status prior to study enrollment. For most forms of hormone replacement therapy, at&#xD;
             least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this&#xD;
             interval depends on the type and dosage of hormone replacement therapy. Following&#xD;
             confirmation of their post-menopausal status, they can resume use of hormone&#xD;
             replacement therapy during the study.&#xD;
&#xD;
          -  Body mass index within the range 19 - 32kg/m2 (inclusive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ALT, alkaline phosphatase and bilirubin greater than 1.5xULN (isolated bilirubin&#xD;
             greater than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin&#xD;
             less than 35%.&#xD;
&#xD;
          -  Current or chronic history of inflammatory bowel disease, chronic diarrhea, Crohn's&#xD;
             disease or malabsorption syndromes.&#xD;
&#xD;
          -  Current or chronic history of cholelithiasis, inflammatory gall bladder disease,&#xD;
             cholestatic liver injury, and cholecystectomy.&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic abnormalities (with the&#xD;
             exception of Gilbert's syndrome).&#xD;
&#xD;
          -  Fecal occult blood positive test at screening.&#xD;
&#xD;
          -  Triglycerides greater than 250mg/dL.&#xD;
&#xD;
          -  History of chronic or acute pancreatitis.&#xD;
&#xD;
          -  Mean QTc greater than and equal to 450msec on three tracings obtained at least 5&#xD;
             minutes apart.&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening.&#xD;
&#xD;
          -  A positive test for HIV antibody.&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen. A minimum list of drugs that will be&#xD;
             screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and&#xD;
             benzodiazepines.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as an&#xD;
             average weekly intake of greater than 14 drinks for males or greater than 7 drinks for&#xD;
             females. One drink is equivalent to 12g of alcohol: 12 ounces (360mL) of beer, 5&#xD;
             ounces (150mL) of wine or 1.5 ounces (45mL) of 80 proof distilled spirits.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days or 5 half-lives of the investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Unable to refrain from the use of prescription or non-prescription drugs, including&#xD;
             vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or&#xD;
             14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is&#xD;
             longer) prior to the first dose of study medication, unless in the opinion of the&#xD;
             Investigator and GSK Medical Monitor the medication will not interfere with the study&#xD;
             procedures or compromise subject safety.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the Investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500mL within a 56-day period.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
          -  Subject is either an immediate family member of a participating investigator, study&#xD;
             coordinator, employee of an investigator; or is a member of the staff conducting the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>May 17, 2012</study_first_submitted>
  <study_first_submitted_qc>May 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2012</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <keyword>intestinal bile acid transporter inhibitor</keyword>
  <keyword>GSK2330672</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>GSK1614235</keyword>
  <keyword>dose escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>116511</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116511</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116511</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116511</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116511</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116511</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116511</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

